Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivabradine
- Development stage
- Approved
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ivabradine is a small molecule drug used primarily for the symptomatic management of chronic heart failure and stable angina pectoris. It acts as a selective inhibitor of the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels—specifically targeting the "funny" current (If) in the sinoatrial node. By inhibiting these channels, ivabradine slows pacemaker activity and reduces heart rate without affecting myocardial contractility or blood pressure. This mechanism allows for improved oxygen supply to cardiac tissue and reduced risk of hospitalization due to worsening heart failure. Ivabradine is approved for use in adults with chronic heart failure with reduced ejection fraction and in children aged 6 months or older with dilated cardiomyopathy[1][3][4][5][6].
- Brand names
- CorlanorProcoralan
- Other names
- ivabradineivabradine hydrochloride
02
Targets
HCN4 (Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4)HCN2 (Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2)
Beyond the preview
Go deeper on ivabradine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivabradine.